Suono Bio is based on MIT research and is aiming to use low-frequency ultrasound to bring therapeutic compounds to target cells with greater efficiency.
Suono Bio, a US-based drug delivery technology developer based on Massachusetts Institute of Technology (MIT) research, has received an undisclosed sum of funding from diversified imaging and medical group Fujifilm.
Founded in 2017, Suono Bio is developing medications for inflammatory-mediated diseases that will exploit its drug delivery technology to ensure compounds reach target cells quickly and efficiently.
Suono Bio’s approach uses low-frequency ultrasound to help administer small molecules, biologics and nucleic acids into the body, potentially facilitating the creation of…
